DelveInsight's analysis estimates that the postherpetic neuralgia market is expected to show positive growth, mainly attributed to increased incidence and the anticipated launch of novel therapies during the forecasted period (2024–2034). LAS VEGAS , June 10, 2024 /PRNewswire/ -- DelveInsight's Postherpetic Neuralgia Market Insights report includes a comprehensive understanding of current treatment practices, postherpetic neuralgia emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [ the United States , the EU4 ( Germany , France , Italy , and Spain ) and the United Kingdom , and Japan ]. Key Takeaways from the Postherpetic Neuralgia Market Report According to DelveInsight's analysis, the total market size of postherpetic neuralgia in the 7MM is approximately USD 100 million in 2023 and is projected to increase during the forecast period (2024–2034).
As per DelveInsight's estimates, the total incident cases of postherpetic neuralgia in the 7MM were approximately 600K in 2023. These cases are expected to increase by 2034. Approximately 40–50% of patients with PHN do not respond to any treatment, and other patients experience limited efficacy.
Leading postherpetic neuralgia companies such as Lexicon Pharmaceuticals, Merz Therapeutics , and others are developing novel postherpetic neuralgia drugs that can be available in the postherpetic neuralgia market in the coming years. The promising posth.